The relationship between lactate dehydrogenase and apolipoprotein A1 levels in patients with severe pneumonia
Lactate Dehydrogenase and Apolipoprotein A1 in Severe Pneumonia
Abstract
Background: To investigate the relationship between lactate dehydrogenase and apolipoprotein A1 levels and the condition and prognosis of patients with severe pneumonia.
Methods: We retrospectively collected 204 patients with severe pneumonia who were hospitalized from January 1, 2019 to December 1, 2021 in our hospital (respiratory intensive care unit (RICU)), and divided into survival group (160 patients) and death group (44 patients) according to their hospitalization outcome. The relationship between lactate dehydrogenase and apolipoprotein A1 levels and general information, disease, and treatment needs of patients with severe pneumonia was analyzed, and lactate dehydrogenase, apolipoprotein A1, neutrophil-to-lymphocyte ratio, hematocrit, C-reactive protein, calcitoninogen, D-dimer, Acute Physiology and Chronic Health Status Rating System II, and Pneumonia Severity Index scores were compared between the survival and death groups. The value of these indicators in determining the prognosis of patients was analyzed using subject operating characteristic (ROC) curves. Logistic regression was used to analyze the risk factors for death from severe pneumonia.
Results: The differences were statistically significant (P<0.05) when comparing age and pneumonia typing between the two groups. There was no statistically significant difference between the two groups in terms of gender and total length of stay (P >0.05). There was no statistically significant difference in LDH and ApoA1 levels between male patients and female patients (P>0.05). The differences in LDH and ApoA1 levels were statistically significant (P<0.05) when comparing patients with severe pneumonia at different ages. The differences in LDH and ApoA1 levels between SCAP and SHAP patients were not statistically significant (P>0.05). LDH and ApoA1 levels were higher in patients with severe pneumonia with acute exacerbation of slow-onset lung or MODS during hospitalization than in patients with severe pneumonia without acute exacerbation of slow-onset lung or MODS, with statistically significant differences (P<0.05). The differences were statistically significant (P<0.05) when comparing LDH and ApoA1 levels in patients with severe pneumonia with different PSI grades or APACHE II scores. The differences were statistically significant (P<0.05) when comparing LDH and ApoA1 levels in patients with severe pneumonia with different ICU length of stay. There was no statistically significant difference in LDH and ApoA1 levels when comparing patients with severe pneumonia who required tracheal intubation or sedation and analgesia during hospitalization (P>0.05). LDH and ApoA1 levels in patients with severe pneumonia with different duration of mechanical ventilation were compared with statistically significant differences (P<0.05). LDH and ApoA1 levels in the death group were 105.08 (75.22 ~140.0), which was significantly higher than 86.66 (62.66 ~ 106.14) in the survival group, with statistically significant differences (P<0.05). There was no statistically significant difference in the levels of NLR, HCT, CRP, PCT, DD, PSI scores, and APACHE II scores between the two groups (P>0.05). The AUC for LDH predicting death in patients with severe pneumonia was 0.723 (95% CI (0.579 ~ 0.868)) with a sensitivity of 70.7% and specificity of 71.8% at a cut-off value of 289 U/mL, and the AUC for ApoA1 predicting death in patients with severe pneumonia was 0.754 (95% CI (0.616 ~ 0.891)) with a cut-off value of at 0.92 mg/mL, the sensitivity was 72.2% and specificity was 73.1%, and the AUC for LDH combined with ApoA1 to predict death in patients with severe pneumonia was 0.873 (95% CI (0.779 ~ 0.967)), with a higher area under the line than for the assay alone, with a sensitivity of 85.14% and specificity of 82.83%. Multifactorial dichotomous logistic regression analysis revealed that LDH>289 U/mL and ApoA1<0.92 mg/mL would increase the risk of death from severe pneumonia, with statistically significant differences (OR=4.275, 0.548, P<0.05).
Conclusion: Elevated LDH levels and reduced ApoA1 levels in patients with severe pneumonia are valuable in assessing patients' conditions and prognosis, and can provide assistance in the early assessment of patients' conditions and diagnosis and treatment.
References
1. Ceccato A, Russo A, Barbeta E, Oscanoa P, Tiseo G, Gabarrus A, et al. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. Crit Care 2021; 25(1): 432.
2. Mahmoodpoor A, Shadvar K, Sanaie S, Hadipoor MR, Pourmoghaddam MA, Saghaleini SH. Effect of Vitamin C on mortality of critically ill patients with severe pneumonia in intensive care unit: a preliminary study. Bmc Infect Dis 2021; 21(1): 616.
3. Qu J, Zhang J, Chen Y, Huang Y, Xie Y, Zhou M, et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infec 2022; 11(1): 556-66.
4. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med 2020; 38(9): 1722-6.
5. Poynard T, Deckmyn O, Rudler M, Peta V, Ngo Y, Vautier M, et al. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Plos One 2020; 15(11): e242306.
6. Modi AR, Kovacs CS. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. Clev Clin J Med 2020; 87(10): 633-9.
7. Restrepo MI, Bienen T, Mortensen EM, Anzueto A, Metersky ML, Escalante P, et al. Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey. Chest 2008; 133(3): 828-9.
8. Baek MS, Park S, Choi JH, Kim CH, Hyun IG. Mortality and Prognostic Prediction in Very Elderly Patients With Severe Pneumonia. J Intensive Care Med 2020; 35(12): 1405-10.
9. Guo Q, Song WD, Li HY, Zhou YP, Li M, Chen XK, et al. Correction to: Scored minor criteria for severe community-acquired pneumonia predicted better. Resp Res 2019; 20(1): 147.
10. Ma CM, Wang N, Su QW, Yan Y, Yin FZ. The Performance of CURB-65 and PSI for Predicting In-Hospital Mortality of Community-Acquired Pneumonia in Patients with Type 2 Diabetes Compared with the Non-Diabetic Population. Diabet Metab Synd Ob 2021; 14: 1359-66.
11. Kim MA, Park JS, Lee CW, Choi WI. Pneumonia severity index in viral community acquired pneumonia in adults. Plos One 2019; 14(3): e210102.
12. Zhao Y, Yin L, Patel J, Tang L, Huang Y. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis. J Med Virol 2021; 93(7): 4358-69.
13. Gupta GS. The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients. Inflammation 2022; 45(6): 2091-123.
14. Kojima K, Yoon H, Okishio K, Tsuyuguchi K. Increased lactate dehydrogenase reflects the progression of COVID-19 pneumonia on chest computed tomography and predicts subsequent severe disease. Sci Rep-Uk 2023; 13(1): 1012.
15. Lee E, Choi I. Clinical Usefulness of Serum Lactate Dehydrogenase Levels in Mycoplasma pneumoniae Pneumonia in Children. Indian J Pediatr 2022; 89(10): 1003-9.
16. Zhu Z, Yang Y, Fan L, Ye S, Lou K, Hua X, et al. Low serum level of apolipoprotein A1 may predict the severity of COVID-19: A retrospective study. J Clin Lab Anal 2021; 35(8): e23911.
17. Faguer S, Del BA, Danet C, Renaudineau Y, Izopet J, Kamar N. Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study. Front Pharmacol 2022; 13: 936659.
18. Hilser JR, Han Y, Biswas S, Gukasyan J, Cai Z, Zhu R, et al. Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection. J Lipid Res 2021; 62: 100061.
19. Huang D, He D, Gong L, Wang W, Yang L, Zhang Z, et al. Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus. Crit Care 2021; 25(1): 419.
20. Vidaur L, Totorika I, Montes M, Vicente D, Rello J, Cilla G. Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis. Ann Intensive Care 2019; 9(1): 86.
21. Yan LP, Liu ZB, Wu M, Ge YP, Zhang Q. Effect of lncRNA MALAT1 expression on survival status of elderly patients with severe pneumonia. Eur Rev Med Pharmaco 2020; 24(7): 3959-64.
22. Rosas-Carrasco O, Nunez-Fritsche G, Lopez-Teros MT, Acosta-Mendez P, Cruz-Onate JC, Navarrete-Cendejas AY, et al. Low muscle strength and low phase angle predicts greater risk to mortality than severity scales (APACHE, SOFA, and CURB-65) in adults hospitalized for SARS-CoV-2 pneumonia. Front Nutr 2022; 9: 965356.
23. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med 2020; 130(5): 390-9.
24. Fang C, Xu L, Li Y, Wei S, Zhao Z, Zhao Z. Clinical Epidemiology, Treatment, and Prognostic Factors of Hospital-Acquired Pneumonia Caused by the Extensively Drug-Resistant Acinetobacter Baumannii. Clin Lab 2023; 69(1):
25. Liu B, Zhang Q. Establishment and Validation of the Risk Nomogram of Poor Prognosis in Patients with Severe Pulmonary Infection Complicated with Respiratory Failure. Int J Gen Med 2023; 16: 2623-32.
Copyright (c) 2023 Jiang Wang, Ronghua Wang, Ying Zhou, Yao Ma, Chunyan Xiong
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.